Biologic therapy in Phoenix: planning office care using blood or tissue

Which clinic route to check

The Banner Estrella location could shorten the drive for central or west Phoenix. Reach it by I-10, the Papago Freeway, toward 91st Avenue and Thomas Road.

The Scottsdale location may be nearer for Arcadia and north Phoenix. From Ahwatukee, the Chandler location may be easier to reach.

Confirm the exact address before leaving home. The clinic with the shortest drive isn't always inside Phoenix.

What time to allow

Ask how long the exam takes and whether a procedure could happen that day. Ask how many return trips the clinic expects.

A short appointment can still mean a long outing in traffic. If you'll need a driver, count that person's time too.

Soreness after office care may affect your drive home. Check when driving and normal errands can begin again.

Leave extra time when sitting makes the joint stiff. You won't need to hurry from the car into the exam room.

What to bring across town

Bring your medicine list, requested records, and any recent X-ray. Wear loose clothes so the clinician can examine the sore area.

Write down the hour soreness begins and the chores that worsen it. Memory gets less reliable once the visit begins.

Request one total price plus the number of return trips. A nearby first visit won't solve a schedule that you can't keep.

Sources

1. Medicare's national coverage determination states that CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only inside an approved coverage-with-evidence-development clinical study. Every approved study listed under the NCD is a wound-healing study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

2. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

3. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.